Ultra Market Research | Global Chronic Myeloid Leukemia Market
Global Chronic Myeloid Leukemia Market
Report ID : 884
Category : Pharmaceuticals,Global
No Of Pages : 83
Published on: December 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Global Chronic Myeloid Leukemia Market Introduction Chronic Myeloid Leukemia, also known as CML, is a type of blood cancer where the bone marrow produces too many abnormal white blood cells. This is caused by a chromosomal mutation called the Philadelphia chromosome, which results in the production of the BCR-ABL1 fusion gene. The Global Chronic Myeloid Leukemia market has experienced tremendous growth because of advances in diagnostics, treatment options, and awareness campaigns. The market size has valued at several billion dollars with a steady growth curve which is accredited to innovative drug therapies and increased prevalence rates worldwide. Current trends involve the development of targeted therapies such as tyrosine kinase inhibitors, which have revolutionized patient outcomes through the prolongation of survival rates and improvement in quality of life. Global focus on personalized medicine and increased healthcare expenditure has further spurred the development of the market.
Segmentation Therapeutics • Targeted Therapies o Tyrosine Kinase Inhibitors (TKIs) First-generation TKIs Second-generation TKIs Third-generation TKIs Others o Other Targeted Drugs BCR-ABL inhibitors Novel agents • Chemotherapy o Oral Chemotherapy o Intravenous Chemotherapy • Others
Diagnostics • Molecular Diagnostics o Polymerase Chain Reaction (PCR) o Fluorescence In Situ Hybridization (FISH) o Others • Imaging Tests o Bone Marrow Imaging o Advanced Scanning Techniques • Others
End-User • Hospitals o Specialized Oncology Centers o Multi-specialty Hospitals • Diagnostic Laboratories o Public Laboratories o Private Laboratories • Research Institutes o Academic Research o Private Research Organizations • Others
List of Market Players 1. Novartis AG (Switzerland) 2. Bristol-Myers Squibb (USA) 3. Pfizer Inc. (USA) 4. Takeda Pharmaceutical Company (Japan) 5. Sanofi (France) 6. Roche Holding AG (Switzerland) 7. Bayer AG (Germany) 8. AbbVie Inc. (USA) 9. Incyte Corporation (USA) 10. AstraZeneca (UK) 11. Amgen Inc. (USA) 12. Biogen (USA) 13. Merck & Co., Inc. (USA) 14. GlaxoSmithKline plc (UK) 15. Johnson & Johnson (USA)
Drivers The increasing prevalence of leukemia worldwide, especially in aging populations, is driving the market for Global Chronic Myeloid Leukemia. Advanced diagnostic techniques and targeted therapies significantly enhance early detection and treatment outcomes. Additionally, growing awareness of hematological malignancies and improvements in the infrastructure of healthcare in the emerging economies are contributing to the growth of the market. The innovation also spurred by government initiatives and funding towards cancer research resulted in a healthy pipeline of new drugs. Also, the high success rate of TKIs in managing CML has boosted demand for these therapies worldwide.
Restraints Despite its rapid growth, the market has several challenges. The cost of treatment is very high, especially for targeted therapies, which is a barrier to wide adoption, especially in low-income countries. Advanced healthcare facilities are not easily accessible in underdeveloped regions, further limiting market penetration. Drug resistance to TKIs has also emerged as a significant clinical challenge, and alternative therapies need to be developed. Barriers in regulations and rigorous procedures for approval of new treatments also inhibit market growth. The limited healthcare coverage also restricts the clientele to pay for and access treatment in a few areas.
Opportunities The Chronic Myeloid Leukemia market is a vast space with many scope for innovation and expansion. With the increased concentration on personalized treatment, better, more efficacious, and patient-specific treatments are being developed. Emerging countries with improving health infrastructure and healthcare expenditure patterns are major untapped markets for players in the global area. Moreover, increasing biotechnology and research collaborations are promoting the development of non-toxic, higher efficacy drugs. Another promising area of integration lies in the application of artificial intelligence in diagnostics and drug development, with great potential for revolutionizing the detection and treatment of CML.
Trends Combination therapies are gaining ground in the market to avoid drug resistance and facilitate more effective treatment. More accurate and sensitive mutations associated with CML would be detected with next-generation sequencing as it advances in molecular diagnostics. Telemedicine and digital healthcare platforms are gaining increasing usage in remote regions for the management of CML patients. More recently, value-based healthcare has gained increasing focus, and firms are making efforts to market cost-effective treatment options while biosimilars are more popularly adopted as they cater to providing more affordable alternatives from expensive biologics, thus contributing to expanding access.
Key Target Audience • Pharmaceutical Companies • Oncology Research Centers • Hospitals and Clinics • Diagnostic Laboratories • Academic Institutes • Regulatory Authorities • Investors and Venture Capitalists
Frequently Asked Questions (FAQ's)
Chronic Myeloid Leukemia is a blood cancer caused by genetic mutations in white blood cells.
Key drivers include advancements in targeted therapies, increasing prevalence, and growing awareness of cancer.
Challenges include high treatment costs, drug resistance, and limited access in low-income regions.
Trends include combination therapies, biosimilar adoption, and AI-driven diagnostics
Key players include Novartis AG, Bristol-Myers Squibb, and Pfizer Inc.
1. Introduction 1.1 Report Description 1.2 Research Methodology • 1.2.1 Data Mining • 1.2.2 Market Modelling and Forecasting • 1.2.3 Data Validation • 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation • 3.2.1 By Treatment Type • 3.2.2 By End-User • 3.2.3 By Distribution Channel • 3.2.4 By Geography 3.3 Market Dynamics • 3.3.1 Drivers • 3.3.2 Restraints • 3.3.3 Opportunities • 3.3.4 Challenges
4. Global Chronic Myeloid Leukemia Market by Treatment Type 4.1 Introduction 4.2 Market Size and Growth Rate by Treatment Type (2024-2030) 4.2.1 Targeted Therapies • 4.2.1.1 First-generation Tyrosine Kinase Inhibitors (TKIs) • 4.2.1.2 Second-generation TKIs • 4.2.1.3 Third-generation TKIs • 4.2.1.4 Others 4.2.2 Chemotherapy • 4.2.2.1 Oral Chemotherapy • 4.2.2.2 Intravenous Chemotherapy 4.2.3 Supportive Therapies • 4.2.3.1 Immunotherapy • 4.2.3.2 Bone Marrow Transplantation 4.2.4 Diagnostics • 4.2.4.1 Molecular Testing o 4.2.4.1.1 PCR Testing o 4.2.4.1.2 FISH Testing o 4.2.4.1.3 Others • 4.2.4.2 Imaging Techniques o 4.2.4.2.1 Bone Marrow Biopsy Imaging o 4.2.4.2.2 Scanning Techniques • 4.2.4.3 Genetic Testing
5. Global Chronic Myeloid Leukemia Market by End-User 5.1 Introduction 5.2 Market Size and Growth Rate by End-User (2024-2030) 5.2.1 Hospitals and Clinics • 5.2.1.1 Specialty Hospitals • 5.2.1.2 Oncology Centers 5.2.2 Diagnostic Laboratories • 5.2.2.1 Private Laboratories • 5.2.2.2 Public Laboratories 5.2.3 Research Institutes
6. Global Chronic Myeloid Leukemia Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Hospital Pharmacies • 6.2.1.1 Inpatient Pharmacies • 6.2.1.2 Specialty Pharmacies 6.2.2 Retail Pharmacies • 6.2.2.1 Independent Pharmacies • 6.2.2.2 Chain Pharmacies 6.2.3 Online Pharmacies
7. Global Chronic Myeloid Leukemia Market by Geography 7.1 Introduction 7.2 Market Size and Growth Rate by Region (2024-2030) 7.2.1 North America • 7.2.1.1 United States • 7.2.1.2 Canada 7.2.2 Europe • 7.2.2.1 Germany • 7.2.2.2 France • 7.2.2.3 United Kingdom • 7.2.2.4 Rest of Europe 7.2.3 Asia Pacific • 7.2.3.1 China • 7.2.3.2 Japan • 7.2.3.3 India • 7.2.3.4 Southeast Asia • 7.2.3.5 Rest of Asia Pacific 7.2.4 Latin America • 7.2.4.1 Brazil • 7.2.4.2 Rest of Latin America 7.2.5 Middle East & Africa (MEA) • 7.2.5.1 GCC • 7.2.5.2 North Africa • 7.2.5.3 South Africa • 7.2.5.4 Rest of MEA
8. Competitive Landscape 8.1 Company Profiles 8.1.1 Novartis AG (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Bristol-Myers Squibb (United States) 8.1.3 Pfizer Inc. (United States) 8.1.4 Takeda Pharmaceutical Company (Japan) 8.1.5 Sanofi (France) 8.1.6 Roche Holding AG (Switzerland) 8.1.7 AbbVie Inc. (United States) 8.1.8 AstraZeneca (United Kingdom) 8.1.9 Amgen Inc. (United States) 8.1.10 Incyte Corporation (United States) 8.1.11 Bayer AG (Germany) 8.1.12 GlaxoSmithKline (United Kingdom) 8.1.13 Johnson & Johnson (United States) 8.1.14 Merck & Co. (United States) 8.1.15 Biogen (United States)
9. List of Tables and Figures • Table: Global Chronic Myeloid Leukemia Market Size by Treatment Type (2024-2030) • Table: Regional Segmentation of Market Share (2024) • Figure: Market Growth Trajectory (2018-2030) • Figure: Pipeline Therapies and Market Share Contribution
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Global Chronic Myeloid Leukemia Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Global Chronic Myeloid Leukemia Market for the past year and forecasts for the next six years. Global Chronic Myeloid Leukemia Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Global Chronic Myeloid Leukemia Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Chronic Myeloid Leukemia Market from different application industries in different regions.
Segmentation Therapeutics • Targeted Therapies o Tyrosine Kinase Inhibitors (TKIs) First-generation TKIs Second-generation TKIs Third-generation TKIs Others o Other Targeted Drugs BCR-ABL inhibitors Novel agents • Chemotherapy o Oral Chemotherapy o Intravenous Chemotherapy • Others
Diagnostics • Molecular Diagnostics o Polymerase Chain Reaction (PCR) o Fluorescence In Situ Hybridization (FISH) o Others • Imaging Tests o Bone Marrow Imaging o Advanced Scanning Techniques • Others
End-User • Hospitals o Specialized Oncology Centers o Multi-specialty Hospitals • Diagnostic Laboratories o Public Laboratories o Private Laboratories • Research Institutes o Academic Research o Private Research Organizations • Others
